CLVLF Income Statement - TTM - Clinuvel Pharmaceuticals Limited

Income Statement (TTM)

Clinuvel Pharmaceuticals Limited Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	35	38	43	48	53	57	62	66	68	70	74	78	80	82	85	88	90	91	93	95
Change (%)		8.14	13.02	11.52	9.41	8.60	7.23	6.75	3.44	3.33	5.75	5.43	2.19	2.15	3.93	3.78	1.61	1.59	2.19	2.15
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	8	9	7	4	6	8	8	9	8	7	7	8	7	7	7	8	8	8	8	8
Change (%)		10.07	-26.65	-36.34	41.54	29.35	10.55	9.54	-10.74	-12.04	1.78	1.75	-5.46	-5.77	7.71	7.16	3.98	3.83	0.76	0.76
% of Revenue	22.90	23.31	15.13	8.64	11.17	13.31	13.72	14.08	12.15	10.34	9.95	9.60	8.88	8.20	8.49	8.77	8.97	9.17	9.04	8.92

Gross Operating Profit	27	29	37	44	47	50	53	56	60	63	67	71	73	75	78	80	82	83	85	87
Change (%)		7.57	25.07	20.05	6.38	6.00	6.73	6.30	5.77	5.45	6.20	5.84	3.01	2.92	3.59	3.47	1.39	1.37	2.34	2.28
% of Revenue	77.10	76.69	84.87	91.36	88.83	86.69	86.28	85.92	87.85	89.66	90.05	90.40	91.12	91.80	91.51	91.23	91.03	90.83	90.96	91.08

SG&A	13	14	14	14	16	17	18	19	20	21	23	25	27	29	29	29	28	27	29	32
Change (%)		6.41	0.96	0.95	9.84	8.96	6.47	6.07	4.57	4.37	8.94	8.21	8.64	7.95	0.09	0.09	-3.91	-4.07	10.38	9.40
% of Revenue	36.85	36.26	32.39	29.33	29.44	29.53	29.32	29.14	29.46	29.75	30.65	31.46	33.44	35.34	34.04	32.83	31.05	29.32	31.66	33.91

R&D	-1	-3	-1	1	1	1	1	1	1	1	1	1	1	1	2	2	3	4	6	7
Change (%)		125.75	-59.15	-144.80	18.24	15.42	32.50	24.53	1.07	1.05	0.36	0.36	6.40	6.01	32.07	24.28	44.44	30.77	33.46	25.07
% of Revenue	-3.74	-7.80	-2.82	1.13	1.22	1.30	1.61	1.88	1.83	1.79	1.70	1.62	1.69	1.75	2.22	2.66	3.79	4.87	6.36	7.79

OpEx	20	20	20	20	23	26	28	30	30	30	32	34	36	38	39	40	40	40	45	49
Change (%)		-0.81	-0.59	-0.60	16.41	14.10	7.51	6.99	-0.38	-0.38	7.09	6.62	5.55	5.26	2.13	2.09	0.60	0.59	11.45	10.27
% of Revenue	56.84	52.14	45.86	40.88	43.49	45.69	45.81	45.91	44.22	42.63	43.17	43.66	45.09	46.47	45.66	44.92	44.47	44.03	48.02	51.84

Operating Income	15	18	23	29	30	31	33	36	38	40	42	44	44	44	46	49	50	51	48	46
Change (%)		19.93	27.84	21.78	4.58	4.38	7.00	6.54	6.69	6.27	4.75	4.53	-0.41	-0.41	5.49	5.20	2.44	2.39	-5.09	-5.36
% of Revenue	43.16	47.86	54.14	59.12	56.51	54.31	54.19	54.09	55.78	57.37	56.83	56.34	54.91	53.53	54.34	55.08	55.53	55.97	51.98	48.16

Interest Expense	-2	-3	-2	-2	-2	-2	-2	-2	-2	-3	-3	-3	-4	-4	-4	-4	-4	-4	-4	-4
Change (%)		15.64	-17.41	-30.40	5.34	5.07	5.28	20.61	8.79	8.08	9.69	8.84	11.77	10.53	6.46	6.07	-0.49	-0.49	0.59	0.59
% of Revenue	-6.87	-7.34	-5.37	-3.35	-3.22	-3.12	-3.06	-3.46	-3.64	-3.81	-3.95	-4.08	-4.46	-4.82	-4.94	-5.05	-4.95	-4.85	-4.77	-4.70

Net Income	18	21	23	25	24	24	22	21	24	26	29	31	30	30	33	36	37	39	37	36
Change (%)		16.33	9.08	8.32	-1.25	-1.26	-6.70	-7.19	13.21	11.67	7.97	7.38	-0.74	-0.74	9.09	8.33	4.40	4.22	-3.36	-3.47
% of Revenue	50.74	54.59	52.69	51.18	46.19	41.99	36.54	31.77	34.77	37.58	38.37	39.08	37.95	36.88	38.71	40.41	41.52	42.60	40.29	38.07

Source: Capital IQ

Clinuvel Pharmaceuticals Limited - Income Statement (TTM)

Income Statement (TTM)

Other Listings

DE:UR9
AU:CUV	A$11.28